文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症与脓毒性休克危重患者经验性大剂量美罗培南的临床结局:一项随机对照试验

Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial.
PubMed 文献 · J Intensive Care · 2020-04-15
一句话结论脓毒症与脓毒性休克患者经验性大剂量美罗培南(2 g/3 h q8h)与标准剂量(1 g/3 h q8h)总体临床结局相当,但急诊来源特定亚组微生物学治愈率更高。

该前瞻性随机开放标签研究纳入78例脓毒症与脓毒性休克患者,比较经验性大剂量美罗培南(2 g静脉输注3 h,每8 h一次)与标准剂量(1 g静脉输注3 h,每8 h一次)的临床结局。两组中位mSOFA评分变化均为-1,差异无统计学意义(P=0.75);临床治愈、微生物学治愈、14天与28天死亡率、无血管活性药物天数、无呼吸机天数、ICU与住院-free天数均无差异,不良事件相当。亚组分析显示,急诊来源且mSOFA评分≥7的患者中,大剂量组微生物学治愈率显著更高(75%(9/12)vs 20%(2/10),P=0.03);急诊来源且APACHE II评分>20或使用机械通气的患者中大剂量组微生物学治愈率亦更高。

要点

  • 脓毒症与脓毒性休克患者经验性大剂量美罗培南(2 g/3 h q8h)与标准剂量(1 g/3 h q8h)相比,中位delta mSOFA均为-1,差异无统计学意义(P=0.75)。
  • 两组临床治愈、微生物学治愈、14天与28天死亡率、无血管活性药物天数、无呼吸机天数、ICU与住院-free天数均无差异,不良事件相当。
  • 急诊来源且mSOFA评分≥7的患者中,大剂量组微生物学治愈率75%(9/12)vs 标准剂量组20%(2/10),P=0.03。
  • 急诊来源且APACHE II评分>20的患者中,大剂量组微生物学治愈率83.3%(10/12)vs 28.6%(2/7),P=0.045。
  • 急诊来源且使用机械通气的患者中,大剂量组微生物学治愈率87.5%(7/8)vs 23.1%(3/13),P=0.008。

适用人群与场景

  • 脓毒症与脓毒性休克危重患者,来自急诊科或ICU。
  • 亚组分析人群为急诊来源且mSOFA评分≥7、APACHE II评分>20或使用机械通气的患者。

处置流程与药物剂量

  • 大剂量美罗培南:2 g静脉输注3 h,每8 h一次,经验性治疗。
  • 标准剂量美罗培南:1 g静脉输注3 h,每8 h一次,经验性治疗。

研究设计与关键结果

  • 前瞻性随机开放标签研究,纳入78例脓毒症与脓毒性休克患者,比较高剂量美罗培南(2 g/3 h q8h)与标准剂量(1 g/3 h q8h)。
  • 主要终点中位delta mSOFA:大剂量组-1 vs 标准剂量组-1,P=0.75,差异无统计学意义。
  • 临床治愈、微生物学治愈、14天与28天死亡率、无血管活性药物天数、无呼吸机天数、ICU与住院-free天数两组间无差异;不良事件相当。
  • 急诊来源且mSOFA评分≥7患者:大剂量组微生物学治愈率75%(9/12)vs 标准剂量组20%(2/10),P=0.03。
  • 急诊来源且APACHE II评分>20患者:大剂量组微生物学治愈率83.3%(10/12)vs 标准剂量组28.6%(2/7),P=0.045。
  • 急诊来源且使用机械通气患者:大剂量组微生物学治愈率87.5%(7/8)vs 标准剂量组23.1%(3/13),P=0.008。

证据类型、等级与局限

  • 证据类型:前瞻性随机开放标签研究(RCT)。
  • 试验注册:ClinicalTrials.gov,NCT03344627,注册于2017年11月17日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒症与脓毒性休克患者中,经验性大剂量美罗培南(2 g/3 h q8h)与标准剂量(1 g/3 h q8h)的总体临床结局相当,不改变总体人群的常规剂量选择。
  • 作者认为,急诊来源的脓毒症或脓毒性休克患者中,大剂量美罗培南可能带来更高的微生物学治愈率,尤其在mSOFA评分≥7、APACHE II评分>20或使用机械通气的亚组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Appropriate antimicrobial dosing is challenging because of changes in pharmacokinetics (PK) parameters and an increase in multidrug-resistant (MDR) organisms in critically ill patients. This study aimed to evaluate the effects of an empirical therapy of high-dose versus standard-dose meropenem in sepsis and septic shock patients.

METHODS: We performed a prospective randomized open-label study to compare the changes of modified sequential organ failure assessment (mSOFA) score and other clinical outcomes of the high-dose meropenem (2-g infusion over 3 h every 8 h) versus the standard-dose meropenem (1-g infusion over 3 h every 8 h) in sepsis and septic shock patients. Patients' characteristics, clinical and microbiological outcomes, 14 and 28-day mortality, vasopressor- and ventilator-free days, intensive care unit (ICU) and hospital-free days, percent of the time of antibiotic concentrations above the minimum inhibitory concentration (%T>MIC), and safety were assessed.

RESULTS: Seventy-eight patients were enrolled. Median delta mSOFA was comparable between two groups (- 1 in the high-dose group vs. - 1 in the standard-dose group; P value = 0.75). There was no difference between the two groups regarding clinical and microbiological cure, 14- and 28-day mortality, vasopressor- and ventilator-free days, and ICU- and hospital-free days. In patients admitted from the emergency department (ED) with a mSOFA score ≥ 7, the high-dose group demonstrated significantly better microbiological cure compared with the standard-dose group (75% (9/12 patients) vs. 20% (2/10 patients); P value = 0.03). Likewise, the high-dose group presented higher microbiological cure rate in patients admitted from ED who had either APACHE II score > 20 (83.3% (10/12) vs. 28.6% (2/7); P value = 0.045) or on mechanical ventilator (87.5% (7/8) vs. 23.1% (3/13); P value = 0.008) than the standard-dose group. Adverse events were comparable between the two groups.

CONCLUSIONS: Empirical therapy with the high-dose meropenem presented comparable clinical outcomes to the standard-dose meropenem in sepsis and septic shock patients. Besides, subgroup analysis manifested superior microbiological cure rate in sepsis or septic shock patients admitted from ED.

TRIAL REGISTRATION: ClinicalTrials.gov, NCT03344627, registered on November 17, 2017.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Lertwattanachai T, Montakantikul P, Tangsujaritvijit V, et al. Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial. J Intensive Care. 2020. PMID: 32318268. doi:10.1186/s40560-020-00442-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。